SURGICAL
hamburger
product photo

SEAMLESS BRILLIANCE

The TECNIS Symfony® IOL mitigates the effects of presbyopia so you can empower your patients to see clearly across the full range of vision.

SHARPEST CONTINUOUS VISION

Delivering excellent uncorrected visual acuity (VA) at all distances,1 the TECNIS Symfony® IOL allows your patients to see clearly across a full range of vision.

Defocus Curve1

6-Month Data, Bilaterally Implanted Subjects


  • Sustained 20/25 or better mean VA through 1.5 D
  • Sustained 20/40 or better mean VA through 2.5 D
  • Increase of 1.0 D range of vision throughout the defocus curve

Rather than splitting light into distinct focal points, the TECNIS Symfony® IOL elongates focus, resulting in an increased depth of field. This empowers you to deliver a full range of continuous vision while maintaining high image contrast.

Monocular Contrast Sensitivity at 6 Months1

Mesopic without Glare


ENHANCED FUNCTIONALITY

Deliver the visual quality that allows your patients with and without astigmatism to see clearly in any lighting condition.

  • High-quality distance vision in the presence of astigmatism2
  • Pupil-independent performance enables optimal performance in any lighting condition1
  • Low overall spectacle wear1

The TECNIS Symfony® IOL delivers 20/20 or better vision through 1.5 D of astigmatism.1

85% of patients wear glasses none or a little bit of the time.1

By combining a unique diffractive pattern with achromatic technology, the TECNIS Symfony® IOL delivers outstanding visual acuity over a continuous range of distances while maintaining high contrast performance.

  • Proprietary relief profile elongates focus1
  • Proprietary achromatic technology corrects chromatic aberration and enhances image contrast1

Degree of Difficulty with Visual Symptoms1

Percentage of Eyes, Non-Directed Reports, 6 Months Postoperative


Low incidence of visual symptoms, including halos, glare and starbursts1

LONG-TERM SUSTAINABILITY

Unlike another leading IOL, TECNIS® IOL material is not associated with glistenings,3-7 which can inhibit your patients’ vision. Glistenings cause light scatter, which can result in a reduction in image contrast.4-8

Dark Field Images of Competitor IOL at 10X and 40X Magnification8

TECNIS Symfony® IOL (ZXR00)

OPTIC CHARACTERISTICS

Powers:

+5.0 D to 34.0 D in 0.5 diopter increments

Diameter:

6.0 mm

Center Thickness:

0.7 mm (20.0 D)

Shape:

Biconvex, wavefront-designed anterior aspheric surface, posterior achromatic diffractive surface designed to reduce chromatic aberration for enhanced image contrast and echelette feature to extend the range of vision.

Material:

UV-blocking hydrophobic acrylic

Refractive Index:

1.47 at 35° C

Edge Design:

ProTEC frosted, continuous 360° posterior square edge

BIOMETRY*

CONTACT ULTRASOUND

OPTICAL

A-Constant:

118.8

119.3 

Theoretical AC Depth:

5.40 mm

5.7 mm

Surgeon Factor:9

1.68 mm

1.96 mm

HAPTIC CHARACTERISTICS

Overall Length:

13.0 mm

Thickness:

0.46 mm

Style:

C

Material:

Soft, foldable, UV-blocking hydrophobic acrylic

Design:

TRI-FIX, haptics offset from optic, one-piece lens

View full product specifications (PDF)

IOL INSERTION

Recommended insertion instruments:

CONTACT

Start a TECNIS® IOL trial

LEAVE A LASTING LEGACY

The lens you leave is the life your patients live. Why trust anything less than the very best in optic design?

TECNIS® Family of IOLs

RESOURCES

Directions for Use (PDF)

FOOTNOTES

*Value theoretically derived for a typical 22.0 D lens. Johnson & Johnson Vision recommends that surgeons personalize their A-constant based on their surgical techniques and equipment, experience with the lens model and postoperative results.

REFERENCES

  1. TECNIS Symfony® Extended Range of Vision IOLs DFU. Santa Ana, Calif. Abbott Medical Optics Inc.
  2. Data on File. Abbott Medical Optics Inc. 2016.
  3. Data on File. Abbott Medical Optics Inc. 2013.
  4. Nagata M, et al. Clinical evaluation of the transparency of hydrophobic acrylic intraocular lens optics. J Cataract Refract Surg. 2010 Dec;36(12):2056-2060.
  5. Christiansen G, et al. Glistenings in the AcrySof® intraocular lens: Pilot study. J Cataract Refract Surg. 2001; 27(5):728-733.
  6. Colin J, et al. Incidence of glistenings with the latest generation of yellow- tinted hydrophobic acrylic intraocular lenses. J Cataract Refract Surg. 2012; 38:(7)1140-1146.
  7. Gunenc U, et al. Effects on visual function of glistenings and folding marks in AcrySof® intraocular lenses. J Cataract Refract Surg. 2001; 27(10):1611-1614.
  8. Van der Mooren M, Franssen L, Piers P. Effects of glistenings in intraocular lenses. Biomed Opt Express. 2013;4(8):1294-304.
  9. Calculated based on Holladay I formula: Holladay JT, Prager TC, Chandler TY, Musgrove KH, Lewis JW, Ruiz RS. A three-part system for refining intraocular lens power calculations. J Cataract Refract Surg. 1988;14(1):17-24.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE TECNIS SYMFONY® EXTENDED RANGE OF VISION IOL

Rx Only

INDICATIONS

The TECNIS Symfony® Extended Range of Vision IOL, model ZXR00, is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1.0 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. The model ZXR00 IOL is intended for capsular bag placement only.

WARNINGS

Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio. Patients with any of the following conditions may not be suitable candidates for an intraocular lens because the lens may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition, or may pose an unreasonable risk to the patient’s eyesight: patients with recurrent severe anterior or posterior segment inflammation or uveitis of unknown etiology, or any disease producing an inflammatory reaction in the eye, patients in whom the intraocular lens may affect the ability to observe, diagnose or treat posterior segment diseases, surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure or significant vitreous prolapse or loss), a compromised eye due to previous trauma or developmental defects in which appropriate support of the IOL is not possible, circumstances that would result in damage to the endothelium during implantation, suspected microbial infection, patients in whom neither the posterior capsule nor the zonules are intact enough to provide support for the IOL, children under the age of 2 years are not suitable candidates for intraocular lenses, congenital bilateral cataracts, previous history of, or a predisposition to, retinal detachment, patients with only one good eye with potentially good vision, medically uncontrollable glaucoma, corneal endothelial dystrophy, proliferative diabetic retinopathy. The TECNIS Symfony® IOL should be placed entirely in the capsular bag and should not be placed in the ciliary sulcus. The TECNIS Symfony® IOL may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL. The physician should carefully weigh the potential risks and benefits for each patient, and should fully inform the patient of the potential for reduced contrast sensitivity before implanting the lens in patients. Special consideration of potential visual problems should be made before implanting the lens in patients with macular disease, amblyopia, corneal irregularities, or other ocular disease which may cause present or future reduction in acuity or contrast sensitivity. Because the TECNIS Symfony® IOL may cause a reduction in contrast sensitivity compared to a monofocal IOL, patients implanted with the lens should be informed to exercise special caution when driving at night or in poor visibility conditions. Some visual effects associated with the TECNIS Symfony® IOL may be expected due to the lens design that delivers elongation of focus. These may include a perception of halos, glare, or starbursts around lights under nighttime conditions. The experience of these phenomena will be bothersome or very bothersome in some people, particularly in low-illumination conditions. On rare occasions, these visual effects may be significant enough that the patient may request removal of the IOL. Patients with a predicted postoperative astigmatism greater than 1.0 diopter may not be suitable candidates for implantation with the TECNIS Symfony® IOL, models ZXR00, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower astigmatism. AMO IOLs are single-use devices only. Do not reuse this IOL.

PRECAUTIONS

Prior to surgery, the surgeon must inform prospective patients of the possible risks and benefits associated with the use of this device and provide a copy of the patient information brochure to the patient. When performing refraction in patients implanted with the TECNIS Symfony® IOL, interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is recommended. The ability to perform some eye treatments (e.g. retinal photocoagulation) may be affected by the TECNIS Symfony® IOL optical design. Recent contact lens usage may affect the patient’s refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Do not resterilize the lens. Most sterilizers are not equipped to sterilize the soft acrylic material without producing undesirable side effects. Do not soak or rinse the intraocular lens with any solution other than sterile balanced salt solution or sterile normal saline. Do not store the lens in direct sunlight or at a temperature greater than 113° F (45°C). Do not autoclave the intraocular lens. The surgeon should target emmetropia as this lens is designed for optimum visual performance when emmetropia is achieved. Care should be taken to achieve IOL centration, as lens decentration may result in a patient experiencing visual disturbances under certain lighting conditions. When the insertion system is used improperly, TECNIS Symfony® IOLs may not be delivered properly (i.e., haptics may be broken). Please refer to the specific instructions for use provided with the insertion instrument or system. The safety and effectiveness of TECNIS Symfony® IOLs have not been substantiated in patients with preexisting ocular conditions and intraoperative complications (see below for examples). Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient with one or more of these conditions: [before surgery] pupil abnormalities, prior corneal refractive or intraocular surgery, choroidal hemorrhage, chronic severe uveitis, concomitant severe eye disease, extremely shallow anterior chamber, medically uncontrolled glaucoma, microphthalmos, non-age-related cataract, proliferative diabetic retinopathy (severe), severe corneal dystrophy, severe optic nerve atrophy, irregular corneal astigmatism, amblyopia, macular disease, pregnancy, [during surgery] excessive vitreous loss, non-circular capsulotomy/capsulorhexis, the presence of radial tears known or suspected at the time of surgery, situations in which the integrity of the circular capsulotomy/capsulorhexis cannot be confirmed by direct visualization, cataract extraction by techniques other than phacoemulsification or liquefaction, capsular rupture, significant anterior chamber hyphema, uncontrollable positive intraocular pressure, zonular damage. Potential adverse effects (e.g., complications) associated with the use of the device include the following: infection (endophthalmitis), hypopyon, IOL dislocation, cystoid macular edema, corneal edema, pupillary block, iritis, retinal detachment/tear, raised IOP requiring treatment, visual symptoms requiring lens removal, tilt and decentration requiring repositioning, residual refractive error resulting in secondary intervention. Secondary surgical interventions include, but are not limited to: lens repositioning (due to decentration, rotation, subluxation, etc.), lens replacement, vitreous aspirations or iridectomy for pupillary block, wound leak repair, retinal detachment repair, corneal transplant, lens replacement due to refractive error, unacceptable optical/visual symptoms, severe inflammation.

SERIOUS ADVERSE EVENTS

The most frequently reported serious adverse events that occurred during the clinical trial of the TECNIS Symfony® Lens were cystoid macular edema (2 eyes, 0.7%) and surgical reintervention (treatment injections for cystoid macular edema and endophthalmitis, 2 eyes, 0.7%). One eye was reported with pupillary capture and the eye that had endophthalmitis also had a small hypopyon. No other serious adverse events and no lens-related adverse events occurred during the trial.

ATTENTION

Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE TECNIS® MONOFOCAL 1-PIECE IOL

INDICATIONS

TECNIS® 1-Piece Lenses are indicated for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extra capsular cataract extraction. These devices are intended to be placed in the capsular bag.

WARNINGS

Physicians considering lens implantation should weigh the potential risk/benefit ratio for any conditions described in the TECNIS® 1-Piece IOL Directions for Use that could increase complications or impact patient outcomes.

See Full Indications and Important Safety Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE UNFOLDER® PLATINUM 1 SERIES IMPLANTATION SYSTEM

INDICATIONS

The Model DK7796 Handpiece is used in combination with the Model 1MTEC30 Cartridge to fold and assist in inserting AMO Acrylic 1-Piece Intraocular Lenses, ONLY into the capsular bag. 

CONTRAINDICATIONS

Do not use the handpiece if the rod tip appears nicked or damaged in any way.

WARNINGS

The UNFOLDER® Platinum 1 Series Implantation System should be used ONLY with AMO Acrylic 1-Piece IOLs. Do not use if the cartridge tip is cracked or split prior to implantation. Never release the plunger until the optic body has been completely released from the cartridge tube.

See Full Indications and Important Safety Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE UNFOLDER® EMERALD SERIES IMPLANTATION SYSTEM

INDICATIONS

The UNFOLDER® Emerald Series Implantation System is used to fold and assist in inserting AMO acrylic intraocular lenses, ONLY into the capsular bag.

WARNINGS

The UNFOLDER® Emerald Series Implantation System should only be used with AMO acrylic OptiEdge IOLs. Do not use this device or any of its components with any other lens. If the cartridge tip is cracked or split prior to implantation, do not use.

See Full Indications and Important Safety Information.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE ONE SERIES ULTRA CARTRIDGE IMPLANTATION SYSTEM

Rx Only

INDICATIONS

The DK7786 handpiece with the One Series Ultra cartridge implantation system is used to fold and assist in inserting TECNIS® 1-Piece intraocular lenses (IOL), ONLY into the capsular bag.

CONTRAINDICATIONS

Do not use the handpiece if the rod tip appears nicked or damaged in any way.

WARNINGS

The DK7786 handpiece with the One Series Ultra cartridge implantation system should only be used with TECNIS® 1-Piece IOLs. Do not use if the cartridge tip is cracked or split prior to implantation. Never release the plunger until the optic body has been completely released from the cartridge tube.

See Full Indications and Important Safety Information.

ATTENTION

Reference the Directions for Use labeling for a complete listing of Indications and Important Safety Information.

PP2017MLT0200

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. All other trademarks are the intellectual property of their respective owners.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2017 Abbott Laboratories Inc. Abbott Park, Illinois, USA. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. All other trademarks are the intellectual property of their respective owners.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. All other trademarks are the intellectual property of their respective owners.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO